High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever

Tropical Doctor

Volumn 40, Issue 1, 2010, Pages 27-30

  Dilber, Embiya ^a   Cakir, Murat ^a   Erduran, Erol ^a   Koksal, Iftihar ^b   Bahat, Elif ^a   Mutlu, Mehmet ^a   Celtik, Ahmet Yilmaz ^a   Okten, Aysenur ^a  

^a Department of Pediatrics ^*  (United States)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; METHYLPREDNISOLONE; VIRUS RNA;

ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HEMOPHAGOCYTIC SYNDROME; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALAISE; MALE; MELENA; MYALGIA; NEUTROPENIA; PANCYTOPENIA; PATIENT MONITORING; RISK FACTOR; SCHOOL CHILD; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS HEMORRHAGIC FEVER;

ANTI-INFLAMMATORY AGENTS; CHILD; FEMALE; FEVER; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MALE; METHYLPREDNISOLONE; PLATELET COUNT; TREATMENT OUTCOME; TURKEY;

EID: 75449094848     PISSN: 00494755     EISSN: 17581133     Source Type: Journal    
DOI: 10.1258/td.2009.090069     Document Type: Article

References (27)

1. Charrel RN, Attoui H, Butenko AM, et al., Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect, 2004;10:1040-55
2. Morikawa S, Saijo M, Kurane I. Recent progress in molecular biology of Crimean-Congo haemorrhagic fever. Comp Immunol Microbiol Infect Dis, 2007;30:375-89
3. Ministry of Health. Reports of the Communicable Diseases Department. Ankara, Turkey: Ministry of Health, 2005 (in Turkish)
4. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis, 2006;6:203-14
5. Cevik MA, Erbay A, Bodur H, et al., Clinical and laboratory features of Crimean-Congo haemorrhagic fever: predictors of fatality. Int J Infect Dis, 2008;12:374-9
6. Ergonul O. Treatment of Crimean-Congo haemorrhagic fever. Antiviral Res, 2008;78:125-31
7. Ergonul O, Celikbaş A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo haemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis, 2004;39:284-7
8. Andersson I, Lundkvist A, Haller O, Mirazimi A. Type I interferon inhibits Crimean-Congo haemorrhagic fever virus in human target cells. J Med Virol, 2006;78:216-22
9. Vassilenko SM, Vassilev TL, Bozadjiev LG, Bineva IL, Kazarov GZ. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet, 1990;335:791-2
10. Ozsoylu S. High dose intravenous methylprednisolone for acquired aplastic anaemia, Diamond-Blackfan syndrome and aregenerative anaemias. Br J Haematol, 1989;73:432
11. Tasdelen Fisgin N, Fisgin T, Tanyel E, et al., Crimean-Congo haemorrhagic fever: five patients with hemophagocytic syndrome. Am J Hematol, 2008;83:73-6
12. Doganci L. New insights on the bleeding disorders in CCHF. J Infect, 2007;55:379-81
13. Vorou R, Pierroutsakos IN, Maltezou HC. Crimean-Congo haemorrhagic fever. Curr Opin Infect Dis, 2007;20:495-500
14. Whitehouse CA. Crimean-Congo haemorrhagic fever. Antiviral Res, 2004;64:145-60
15. Hoogstraal H. The epidemiology of tick-borne Crimean-Congo haemorrhagic fever in Asia, Europe, and Africa. J Med Entomol, 1979;15:307-417
16. Schnittler HJ, Feldmann H. Viral haemorrhagic fever–a vascular disease?. Thromb Haemost, 2003;89:967-72
17. Onguru P, Akgul EO, Akinci E, et al., High serum levels of neopterin in patients with Crimean-Congo haemorrhagic fever and its relation with mortality. J Infect, 2008;56:366-70
18. Papa A, Bino S, Velo E, Harxhi A, Kota M, Antoniadis A. Cytokine levels in Crimean-Congo haemorrhagic fever. J Clin Virol, 2006;36:272-6
19. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo haemorrhagic fever. J Infect Dis, 2006;193:941-44
20. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am, 1998;12:435-44
21. Sonmez M, Aydin K, Durmus A, et al., Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo haemorrhagic fever. J Infect, 2007;55:184-7
22. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis, 2000;6:601-8
23. Karti SS, Odabasi Z, Korten V, et al., Crimean-Congo haemorrhagic fever in Turkey. Emerg Infect Dis, 2004;10:1379-84
24. Tristano AG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit, 2008;14:27-36
25. Erduran E, Gedik Y, Sen Y, Yildiran A. Successful treatment of reactive hemophagocytic syndrome with cyclosporin A and intravenous immunoglobulin. Turk J Pediatr, 2000;42:168-70
26. Stabile A, Bertoni B, Ansuini V, La Torraca I, Sallì A, Rigante D. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age. Eur Rev Med Pharmacol Sci, 2006;10:53-9
27. Lee ACW, Wong LG. Haemophagocytic lymphohistiocytosis, Kawasaki disease and use of intravenous immunoglobulin. HK J Paediatr, 2007;12:300-2